Amedica spinal implant cleared
This article was originally published in The Gray Sheet
Executive Summary
Firm debuts the first ceramic spinal implants following 510(k) clearance of its Arx ceramic spinal spacer system, announced March 1. The Arx system is designed to replace collapsed or damaged vertebral bodies in the thoracolumbar region of the spine. Based on Amedica's MC2 technology, the ceramic replacements offer strength and the ability to bind with bone without the interference during diagnostic imaging that titanium implants can cause, the firm says. The market for spinal spacers is estimated to exceed $600 mil. annually...
You may also be interested in...
Financings In Brief
TransMedics: Funds totaling $29.75 mil. raised in a recent Series C financing led by 3i Group will be used to support expanded clinical trials for TransMedics' Organ Care System. The organ transport system is designed to optimize organ health and increase the number of usable transplant organs by maintaining the tissue in a warm, functioning state outside of the body. The firm anticipates European approval for the system for heart transplants in early 2007 following the completion of its PROTECT trial in the UK. Thanks to the funds raised, TransMedics plans to initiate trials in the U.S. and Europe and to extend its platform for use with additional organs such as the lungs, liver and kidneys...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.